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Introduction
Chemotherapy given as adjuvant therapy after surgery to
patients with primary operable breast cancer reduces the
subsequent risk of relapse and death [1]. Although the
absolute reduction in mortality is only about 10–12%, most
patients now receive adjuvant chemotherapy because it is
not possible to identify, at the start of treatment, which
patients might gain benefit. Our approach to this problem
COX = cytochrome c oxidase; FNA = fine needle aspiration; HMG1 = high-motility group protein 1; PCR = polymerase chain reaction; RT =
reverse transcriptase.
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Abstract
Background: Drug resistance in breast cancer is a major obstacle to successful chemotherapy. In this
study we used cDNA microarray technology to examine gene expression profiles obtained from fine
needle aspiration (FNA) of primary breast tumors before and after systemic chemotherapy. Our goal
was to determine the feasibility of obtaining representative expression array profiles from limited
amounts of tissue and to identify those expression profiles that correlate with treatment response.
Methods: Repeat presurgical FNA samples were taken from six patients who were to undergo primary
surgical treatment. Additionally, a group of 10 patients who were to receive neoadjuvant chemotherapy
underwent two FNAs before chemotherapy (adriamycin 60 mg/m2 and cyclophosphamide 600 mg/m2)
followed by another FNA on day 21 after the first cycle. Total RNA was amplified with T7 Eberwine’s
procedure and labeled cDNA was hybridized onto a 7600-feature glass cDNA microarray.
Results: We identified candidate gene expression profiles that might distinguish tumors with complete
response to chemotherapy from tumors that do not respond, and found that the number of genes that
change after one cycle of chemotherapy was 10 times greater in the responding group than in the non-
responding group.
Conclusion: This study supports the suitability of FNA-derived cDNA microarray expression profiling of
breast cancers as a comprehensive genomic approach for studying the mechanisms of drug resistance.
Our findings also demonstrate the potential of monitoring post-chemotherapy changes in expression
profiles as a measure of pharmacodynamic effect and suggests that these approaches might yield
useful results when validated by larger studies.
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has been to give the chemotherapy before surgery (neoadju-
vant therapy) to use the response in the primary tumor as a
surrogate marker of subsequent survival benefit [2]. Predic-
tions of response have been attempted on the basis of tumor
expression of proliferation and apoptosis markers [3],
endocrine and growth factors, and oncogenes [4]. However,
no single tumor marker has been shown to possess a suffi-
cient predictive value to render it clinically useful. To achieve
a greater predictive value, multiple markers need to be exam-
ined and correlated with the response of tumor cells to
chemotherapy. The development of cDNA microarray tech-
nology has provided such an opportunity. With this technol-
ogy it has been possible to identify new classes in breast
cancer according to their gene expression patterns and to
correlate them with distinct clinical outcomes [5,6]. We have
demonstrated previously that RNA amplification is suitable
and reliable for the determination of gene expression profiles
by using small amounts of RNA from core biopsies [7].
Our goal in this project was to determine the feasibility of
obtaining representative cDNA expression array profiles
from fine needle aspirations (FNAs) performed on breast
carcinomas, which are known to have substantial hetero-
geneity after RNA amplification. We also evaluated the
correlation between such profiles and subsequent clinical
responses after neoadjuvant chemotherapy to determine
whether this might provide a useful approach to response
prediction for testing in future prospective studies.
Patients and methods
Patients
All patients provided informed consent before any proce-
dures. To evaluate the sensitivity and reproducibility of the
FNA technique, repeat presurgical FNA samples were taken
from six patients. For two patients in this group, correspond-
ing surgical specimens were available. Additionally, a group
of 10 patients with breast cancer, who were treated with
neoadjuvant chemotherapy, were evaluated by using three
FNAs, two performed one week apart and before
chemotherapy (adriamycin 60 mg/m2 and cyclophos-
phamide 600 mg/m2), and the third on day 21 after the first
cycle of chemotherapy. A 23-gauge needle (Oncotech Inc,
Irvine, California, USA) was used for FNA in all cases.
RNA sample and cDNA preparation
From each aspirate a single-cell suspension was made in
2.5 ml of normal saline. Each sample was snap-frozen in
liquid nitrogen and stored at –80°C. All FNA samples con-
tained more than 50% tumor cells as assessed by a cyto-
logical examination of cytospin. The phenol/chloroform
procedure (Trizol®; Gibco, Grand Island, New York, USA)
was used to extract total RNA from each FNA sample.
Total RNA isolated from the MCF10A human mammary
epithelial immortalized cell line served as a common refer-
ence. Two rounds of Eberwine’s RNA amplification proce-
dure were performed, with minor modifications, with total
RNA from tumor FNA specimens and the MCF10A human
mammary epithelial immortalized cell line as described
previously [8]. Labeled cDNAs were prepared from 3 µg
of amplified RNA, hybridized onto a 7600-feature glass
cDNA microarray (NCI) and scanned with a 10 µm resolu-
tion GenePix 4000 scanner (Axon Instruments, Inc, Foster
City, California, USA) as described elsewhere [9].
Data analysis
Expression profiles were analyzed with BRB Array tools,
version 1.03 (Molecular Statistics and Bioinformatics
Section, National Cancer Institute, Bethesda, Maryland,
USA). Only spot-filtered data were considered for the
analysis as described in the Supplementary Material. To
compare gene expression profiles generated from each
FNA–FNA and FNA–surgical specimen pair, we per-
formed an unsupervised hierarchical cluster analysis
[10]. A compound covariate predictor algorithm was
applied to find a set of predictors for classifying each
patient into the two predetermined classes (good
responders versus bad responders) [11]. A cross-vali-
dated approach was performed to validate the class pre-
diction: one patient was removed; the classifier was
trained on the remaining patients and then tested for its
ability to classify the withheld patient. To estimate the
probability of obtaining the predicting membership purely
by chance we performed random groupings of patients
and we calculated the number of misclassifications (see
Supplementary Material).
Real-time quantitative RT–PCR
Gene expression was measured with the GeneAmp 5700
Sequence Detector (Applied Biosystems, Foster City, Cali-
fornia, USA). Primers and probes (BioServe Biotechnolo-
gies, Laurel, Maryland, USA) were designed with Primer
Express software (see Supplementary Material) (Applied
Biosystems). The following mRNAs were evaluated: CD44,
HMG1, COX17, and ACTB as a normalizing control. Gene
expression in each patient sample was then compared with
expression in the reference cell line, MCF10A.
Results
FNAs can be used to obtain representative and
reproducible gene expression profiles of breast tumors
To prove the feasibility of using RNA amplification we
compared the gene expression profiles generated from
each FNA with those obtained from the corresponding
surgical specimen by using the unsupervised hierarchical
clustering technique [10]. Two FNA samples out of 14
were rejected because of poor RNA quality (patients 11
and 13). All genes selected after spot filtering (4803
genes) were included in the clustering algorithm (See
Supplementary Material). FNA–surgical specimen and
FNA–FNA pairs from the same patient clustered together
and were closer to each other than any samples from any
other patients (Fig. 1a). Similar results were obtainedPage 3 of 8
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when different distance-based clustering methods were
used (data not shown).
Scatter plots were employed to investigate the level of sim-
ilarity between the cDNA microarray results derived from
various samples (Fig. 1b). When profiles from two FNAs
from the same patient (obtained 1 week apart) were
assessed (Fig. 1b, panels a and b), their Pearson correla-
tion coefficient was very high (r = 0.88 and 0.94). This cor-
relation is comparable to that observed between repeated
hybridizations that we conducted with the same RNA
(r = 0.90–0.94, data not shown). The comparison between
surgical specimen and the corresponding FNAs also
revealed a good correlation (Fig. 1b, panels c and d), albeit
with lower correlation coefficients (r = 0.74, 0.70). In con-
trast, FNA–surgical specimen and FNA–FNA samples from
different patients, as expected, gave distinctly different
expression profiles with Pearson correlation coefficients of
r = 0.38 and r = 0.57, respectively (Fig. 1b, panels e and f).
Pretreatment gene expression profiles are associated
with response or lack of response to chemotherapy in
breast carcinoma
To assess whether cDNA microarray profiles obtained
from FNAs before chemotherapy would be able to differ-
entiate and associate with the response or non-response
to treatment, we studied an additional group of 10
patients with breast cancer who were to receive neoadju-
vant chemotherapy. Patient demographics are shown in
Table 1. Three pretreatment FNA samples out of 20
(patients 1, 3 and 4) were discarded because of an insuffi-
cient percentage of tumor cells. For each gene the
average log expression ratio (ratio of the fluorescent inten-
sities of the spots reflecting the relative level of gene
expression) from the cDNA microarray experiments
obtained from the two independent pretreatment FNAs
was considered for analysis. Thirty-seven genes whose
expression was most significantly different between good
and poor responders were identified (P < 0.01; individual
t-test). These included genes involved in the promotion of
cell death, and chemosensitivity. To define a prediction
model for classifying each patient into the two predeter-
mined classes (good responders versus bad responders)
we used a compound covariate predictor algorithm based
on the expression levels of these 37 genes (Fig. 2a). Using
this compound covariate predictor set of genes and a
cross-validated approach we were able to correctly iden-
tify the response status of all 10 patients. Using 10,000
random permutations we confirmed that chance contribu-
tion to this prediction model was unlikely (P < 0.009) (see
the Methods section and Supplementary Material).
Early gene expression changes after one cycle of
chemotherapy
We also investigated the changes in gene expression after
one cycle of chemotherapy. For this purpose we com-
Available online http://breast-cancer-research.com/content/4/3/R3
Figure 1
FNAs are representative of the entire tumor. (a) Dendrogram
representing similarities in the gene expression profiles between
different FNAs and surgical specimens. FNA–surgical specimen and
FNA–FNA pairs from the same patient clustered together more than
with samples from any other patient. *Surgical specimen. (b)
Representative scatter plots indicating levels of similarity between the
cDNA microarray results comparing different specimens. (panels a and
b) Comparison of log expression ratios derived from two pretreatment
FNAs from the same patient. (panels c and d) Comparison of log
expression ratios derived from surgical specimens and the
corresponding FNAs from two different patients. (panels e and f)
Comparison of log expression ratios derived from two pretreatment
FNAs and from a pretreatment FNA and a surgical specimen from
different patients, respectively. The correlation coefficient of each
comparison is shown at the top left of each panel.pared the gene expression of the FNA taken on day 21
after the first cycle of chemotherapy with the average
gene expression of the two pretreatment samples avail-
able for each patient. One post-treatment FNA out of 10
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Figure 2
Gene expression profiles distinguishing good from poor responders. (a) Hierarchical clustering of 37 genes that defined the class predictor and
whose expression best differentiated good from poor responders before chemotherapy. Each row represents a single gene and each column
represents the average of two available independent FNAs. Green and red squares indicate, respectively, overexpressed and underexpressed
genes in a breast tumor compared with the MCF10A breast cancer cell line (color intensity is proportional to the magnitude of the expression level
ratio). Black squares indicate genes with approximately equivalent expression levels and gray squares indicate missing or filter-excluded data.
Branches representing good responders are shown in blue and those representing poor responders in yellow. (b) Hierarchical clustering of 16
genes whose change in expression best differentiated good from poor responders after one cycle of chemotherapy.
Table 1
Patient demographics
Patient Age Tumor Node ER PgR Clinical Pathological finding
no. (years) size (mm) status status status response (after chemotherapy)
1 42 7 + + n/a CR No surgery
2 37 50 + + n/a MRD No surgery
3 50 19 + + n/a MRD DCIS only
4 56 24 – – n/a MRD No surgery
5 56 50 + – n/a MRD DCIS only
6 48 50 + – n/a SD RID
7 64 40 + – – PR RID
8 47 30 – + n/a SD RID
9 51 50 – + n/a PR RID
10 67 30 – – – SD RID
CR, complete clinical response (no residual palpable disease); ER, estrogen receptor; MRD, minimal residual disease (residual palpable irregularity
that was too small to be measured); n/a, not available; PgR, progestrogen receptor; PR, partial response (more than 50% reduction in
bidimensional measurement); SD, stable disease (between 50% reduction and 25% increase in bidimensional measurement); RID, residual
invasive disease; DCIS, ductal carcinoma in situ.was discarded because of insufficient initial material
(patient 1). In this analysis, outliers were defined as genes
that showed at least a twofold change in their expression
level (post-treatment compared with average pretreat-
ment) in at least three out of five patients in each group.
This was performed to select genes with consistently
altered expression within each group. Using these strin-
gent criteria, the numbers of outliers in the good respon-
ders were more than 10-fold those in the poor responder
group (56 versus 5, respectively). When we used less
stringent gene selection criteria based on the intersect of
the genes that appeared at least once as an outlier, the
good responders again exhibited much greater changes in
gene expression than the poor responders (data not
shown).
To further identify early gene expression changes that best
discriminated the two groups after one cycle of
chemotherapy, we also performed a parametric t-test on
each gene’s log-ratio change value from each patient. As
shown in Fig. 2b, we identified 16 genes whose change in
expression level best differentiated between the two
groups (P < 0.01, individual t-test).
RT–PCR confirmation of microarray findings of selected
genes
To validate our array data, we performed RT–PCR of
selected genes (COX17, HMG1 and CD44) involved in
different molecular pathways identified in Fig. 2a, in the
remaining RNA of all available pretreatment FNA samples.
As shown in Fig. 3, the RT–PCR experiments confirmed
the relative abundances of each of the three tested genes
between good and poor responders obtained in microar-
ray experiments.
Discussion
This study is the first to test the feasibility of obtaining rep-
resentative array profiles from FNAs of breast carcinomas
in a clinical setting. Amplification of tumor RNA from FNAs
was used to achieve adequate signal. Our results demon-
strate that when amplified RNA is used as a template,
array profiles derived from an FNA of a given tumor are
highly reproducible and representative. In addition, the
molecular profiles generated from FNAs of different breast
tumors can be distinguished from one another. Although
the profiles derived from the surgical specimen and the
corresponding FNAs showed discernible differences,
these discrepancies are in the same range as the histo-
logic differences between FNAs and surgical specimens
[2]. Specifically, FNAs are enriched for the less adherent
carcinoma cells and reduced in the stromal components in
comparison with the intact tumor. Therefore, the profile of
FNA samples might be more representative of the biology
of the pure cancer cells because the stromal components
have been removed. Most importantly, however, the com-
posite expression profiles remain intact with repeat FNAs,
such that comparisons between FNAs can be used to dis-
tinguish between different forms of breast tumor.
Our results also suggest that gene expression profiles
obtained before and changes after one cycle of
chemotherapy correlate with response to treatment. In the
analysis of the pretreatment expression profiles, we identi-
fied 37 genes differentially expressed in pretreatment
samples that together could segregate excellent respon-
ders from the poorer responders. Although the ‘leave one
out’ cross-validation approach that we performed with the
profiles from the pretreatment samples suggested that
these 37 genes could correctly classify all patients, our
numbers are small and the results should therefore be
considered exploratory. Nevertheless, the comprehensive
nature of array analysis permits the framing of hypothetical
gene sets even with small sample sizes that can be vali-
Available online http://breast-cancer-research.com/content/4/3/R3
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Figure 3
Real-time quantitative RT–PCR analysis of gene expression confirms
the cDNA micoarray data. Expressions of selected genes were
examined using RT-PCR in all FNA breast tumors. The expression level
of each gene in the tumor samples was compared to the reference
MCF10A cell line. All RT-PCR data have been normalized to β-actin.
White and black columns represent good and poor responders,
respectively.dated with an independent and larger set of breast cancer
patients in a prospective manner.
The change in gene expression as measured by the
number of outliers when comparing the pretreatment and
post-treatment samples seems to be more substantial in
the responder than the non-responder group. This might
be expected because changes in expression should be
associated with the more effective cellular intervention.
Thus, responders and non-responders could be differenti-
ated both by specific gene changes and by the quantity of
the change in expression.
An additional benefit of studying gene expression profiles
is the identification of genes and/or gene pathways, which
might associate with the response or intrinsic resistance
to chemotherapy. Examination of the subset of genes
identified before any treatment (Fig. 2a) revealed that
these ‘discriminators’ are involved in a variety of cellular
functions. This list included transcription factors (ERG and
NFYB), oncogene (DLC1), growth factor receptors (KIT),
genes involved in the ubiquitin–proteasome pathway
(UBPH) and DNA repair and cell death regulators
(HMG1, COX 17, PAPPA, BCL2-like2, GADD34, RPL27
and CD44).
One of these genes, HMG1 (for high-motility group
protein 1), was more highly expressed in responders. This
gene encodes a structure-specific HMG-domain protein
that is evolutionarily conserved. HMG1 binds preferentially
to cruciform DNA, cisplatin-modified DNA, and other dis-
torted structures. Overexpression of HMG1 has been
shown to sensitize cells to cisplatin and carboplatin by
shielding its major DNA adducts from nucleotide excision
repair [12]. Depleting HMG1 and HMG2 from cell
extracts by immunoprecipitation enhances the excision
repair of cisplatin-modified DNA. Furthermore, introducing
HMG2 by transfection enhances the cisplatin sensitivity of
a lung adenocarcinoma cell line [13]. Thus, overexpres-
sion of HMG1 in the group of good responders might
confer an increased sensitivity to the cytotoxic effect of
chemotherapy.
Another interesting finding was the upregulated expres-
sion of COX17 (for cytochrome c oxidase assembly
protein) in the good responders group. This gene encodes
a copper-binding chaperone for cytochrome c oxidase
(COX), the terminal enzyme of the mitochondrial respira-
tory chain. Dysfunction of the mitochondrial respiratory
chain has been associated with apoptosis induction [14].
Interestingly, one of the cytotoxic mechanisms of doxoru-
bicin is to inhibit COX activity [15]. Additionally,
decreased COX expression was observed in doxorubicin-
resistant leukemia K562 cells [16]. Thus, the overexpres-
sion of this cytochrome oxidase would be consistent with
the association with better responders.
Finally, CD44, a main cell-surface receptor for hyaluronic
acid, was downregulated in the group of good respon-
ders. CD44 is involved in matrix adhesion, lymphocyte
activation, and the regulation of tumor proliferation.
Several reports have shown an association between
decreased CD44 expression and facilitation of apoptosis
[17]. One of the mechanisms of this activity is thought to
be the CD95/FAS-triggered induced shedding of CD44.
Clinically, a decrease in CD44v6 expression has also
been linked to a better response of neoadjuvant anthracy-
cline-based treatment in cervical cancer [18].
Similar observations could also be made about genes
whose expression was altered after one cycle of
chemotherapy. For example, Cdk9, which encodes a cat-
alytic subunit of TAK (cyclin T1/P-TEFb) and has been
shown to have an antiapoptotic function during monocyte
differentiation [19], was induced in the group of poor
responders after the first treatment. TIMP-1, a collagenase
inhibitor that was downregulated in the good responders,
has been reported to control the cell growth phenotype
during breast cancer development in an autocrine and
paracrine manner [20]. Finally, DCTD, a gene that tran-
scribes dCMP deaminase and is associated with
increased resistance to cytarabine [21], was also induced
in the poor responders. Taken together, these results indi-
cate that the induction of genes associated with cellular
resistance to chemotherapy seems to be associated with
a poor clinical response, whereas a marker of cell growth
seems to be downregulated in the good responders after
one cycle of chemotherapy.
Our results indicate the complexity of genetic alterations
involving various molecular pathways that might be associ-
ated with intrinsic and/or acquired resistance to
chemotherapy in breast cancer. However, these expres-
sion profiles could represent a distinct signature for drug
resistance in this particular small group of breast cancer
patients. Interestingly, we have found that the dynamic
changes after a single cycle of chemotherapy might
further distinguish good responders from poor respon-
ders. The small numbers in our study preclude the defini-
tive assignment of association genes with response, but
these results have identified a significant list of plausible
candidate markers that should be validated in larger clini-
cal data sets.
In summary, our study demonstrates that expression pro-
files can be obtained in a reproducible manner from the
small amount of RNA obtained from breast tumor FNAs.
Moreover, we provide a proof of principle that profiles
derived before treatment and changes in profiles shortly
after starting treatment might have the potential to predict
clinical outcomes from anthracycline-based chemotherapy
in individual patients. Furthermore, using this approach we
might be able to identify candidate genes and pathways,
Breast Cancer Research    Vol 4 No 3 Sotiriou et al.
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could prove to be useful in identifying targets for the treat-
ment of drug-resistant carcinomas.
Acknowledgements
We are grateful to Dr Richard Simon and Dr Amy Peng, who provided
the BRB ArrayTools software. This work was supported in part by the
‘Fonds National de la Recherche Scientifique’, Belgium, grant Ext 260,
V6/5/2-ILF, 14773 to Christos Sotiriou.
References
1. Early Breast Cancer Trialists’ Collaborative Group: Poly-
chemotherapy for early breast cancer: an overview of the ran-
domised trials. Lancet 1998, 352:930-942.
2. Chang J, Powles TJ, Allred DC, Ashley SE, Clark GM, Makris A,
Assersohn L, Gregory RK, Osborne CK, Dowsett M: Biologic
markers as predictors of clinical outcome from systemic
therapy for primary operable breast cancer. J Clin Oncol 1999,
17:3058-3063.
3. Ellis PA, Smith IE, McCarthy K, Detre S, Salter J, Dowsett M: Pre-
operative chemotherapy induces apoptosis in early breast
cancer. Lancet 1997, 349:849.
4. Chang J, Ormerod M, Powles TJ, Allred DC, Ashley SE, Dowsett
M: Apoptosis and proliferation as predictors of chemotherapy
response in patients with breast carcinoma. Cancer 2000, 89:
2145-2152.
5. Gruvberger S, Ringner M, Chen Y, Panavally S, Saal LH, Borg A,
Ferno M, Peterson C, Meltzer PS: Estrogen receptor status in
breast cancer is associated with remarkably distinct gene
expression patterns. Cancer Res 2001, 61:5979-5984.
6. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H,
Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H,
Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-
Dale AL: Gene expression patterns of breast carcinomas dis-
tinguish tumor subclasses with clinical implications. Proc Natl
Acad Sci USA 2001, 98:10869-10874.
7. Sotiriou C, Chand K, Petersen D, Jazaeri A, Liu ET: Core biopsies
can be used to distinguish differences in expression profiling
by cDNA microarrays. J Mol Diagn 2002, 4:30-36.
8. Eberwine J, Yeh H, Miyashiro K, Cao Y, Nair S, Finnell R, Zettel M,
Coleman P: Analysis of gene expression in single live neurons.
Proc Natl Acad Sci USA 1992, 89:3010-3014.
9. Wang E, Miller LD, Ohnmacht GA, Liu ET, Marincola FM: High-
fidelity mRNA amplification for gene profiling. Nat Biotechnol
2000, 18:457-459.
10. Eisen MB, Spellman PT, Brown PO, Botstein D: Cluster analysis
and display of genome-wide expression patterns. Proc Natl
Acad Sci USA 1998, 95:14863-14868.
11. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M,
Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloom-
field CD, Lander ES: Molecular classification of cancer: class
discovery and class prediction by gene expression monitor-
ing. Science 1999, 286:531-537.
12. He Q, Liang CH, Lippard SJ: Steroid hormones induce HMG1
overexpression and sensitize breast cancer cells to cisplatin
and carboplatin. Proc Natl Acad Sci USA 2000, 97:5768-5772.
13. Arioka H, Nishio K, Ishida T, Fukumoto H, Fukuoka K, Nomoto T,
Kurokawa H, Yokote H, Abe S, Saijo N: Enhancement of cis-
platin sensitivity in high mobility group 2 cDNA-transfected
human lung cancer cells. Jpn J Cancer Res 1999, 90:108-115.
14. Desagher S, Martinou JC: Mitochondria as the central control
point of apoptosis. Trends Cell Biol 2000, 10:369-377.
15. Muller I, Niethammer D, Bruchelt G: Anthracycline-derived
chemotherapeutics in apoptosis and free radical cytotoxicity
(Review). Int J Mol Med 1998, 1:491-494.
16. Denis-Gay M, Petit JM, Mazat JP, Ratinaud MH: Modifications of
oxido-reductase activities in adriamycin-resistant leukaemia
K562 cells. Biochem Pharmacol 1998, 56:451-457.
17. Naot D, Sionov RV, Ish-Shalom D: CD44: structure, function,
and association with the malignant process. Adv Cancer Res
1997, 71:241-319.
18. Costa S, Terzano P, Bovicelli A, Martoni A, Angelelli B, Santini D,
Ceccarelli C, Lipponen P, Erzen M, Syrjanen S, Syrjanen K: CD44
isoform 6 (CD44v6) is a prognostic indicator of the response
to neoadjuvant chemotherapy in cervical carcinoma. Gynecol
Oncol 2001, 80:67-73.
19. Foskett SM, Ghose R, Tang DN, Lewis DE, Rice AP: Antiapop-
totic function of CDK9 (TAK/P-TEFb) in U937 promonocytic
cells. J Virol 2001, 75:1220-1228.
20. Luparello C, Avanzato G, Carella C, Pucci-Minafra I: Tissue
inhibitor of metalloprotease (TIMP)-1 and proliferative behav-
iour of clonal breast cancer cells. Breast Cancer Res Treat
1999, 54:235-244.
21. Schroder JK, Seidelmann M, Kirch HC, Seeber S, Schutte J:
Assessment of resistance induction to cytosine arabinoside
following transfer and overexpression of the deoxycytidylate
deaminase gene in vitro. Leukoc Res 1998, 22:619-624.
22. Tukey JW: Tightening the clinical trial. Control Clin Trials 1993,
14:266-285.
Supplementary material: patients and methods
Patients and collection of samples
At least three cytospin slides were made for each FNA
with the Shandon Cytospin technique (Shandon,
Pittsburgh, Pennsylvania, USA) on 0.5 ml of the cell sus-
pension centrifuged at 500 rev/min for 5 min on 3-amino-
propyltriethoxsilane slides. One of these slides was
stained with May–Grünwald–Giemsa as a representative
cytodiagnosis of the remaining 2 ml of the cell suspension
to be used for RNA extraction. The remaining two slides
were used to determine estrogen receptor and proges-
terone receptor status receptors by immunohistochem-
istry. RNA quality from each FNA was assessed by
visualization of the ratio of 28S to 18S ribosomal RNA on
1% agarose gel. Clinical response was defined as com-
plete or nearly complete response (good response) com-
pared with partial or no response (poor response), which
we have previously defined as the best prediction model
for subsequent relapse or survival advantage and used as
the criteria for response in our previous marker studies [2].
Data analysis
Spot filtering
For each fluorescent channel, the log ratios were normal-
ized by subtracting the median log ratio from each experi-
ment. Spots of any experiment that had a red and/or green
intensity less than 250 units after subtraction of the back-
ground, had a spot size less than 25 pixels, or were
flagged for any experimental reason in more than 10% of
the microarray experiments were filtered out.
Compound covariate predictor
Classification of specimens into one of two predetermined
classes based on gene expression data was performed
with a compound covariate predictor. The predictor was
built in two steps. First, a standard two-sample t-test was
performed to identify genes with significant differences (at
level a) in log expression ratios between the two classes.
Second, the log expression ratios of differentially
expressed genes were combined into a single compound
covariate [22] for each specimen; the compound covariate
was used as the basis for class prediction. The compound
covariate for specimen i was defined as
Ci = Σtjxij,
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classes with respect to gene j, xij is the log ratio measured
in specimen i for gene j, and the sum is over all differen-
tially expressed genes. Then the specimen to be classified
was removed from the data set and the remaining speci-
mens (comprising the training set) were used to determine
the differentially expressed genes between the two
classes. Using the log expression ratios of these genes,
the value of the compound covariate was computed for
every specimen in the training set and a classification
threshold was calculated (the midpoint of the means of
the compound covariates for the two classes was used as
the threshold). The class of the omitted specimen was
then predicted by computing the value of the compound
covariate for the specimen, and which side of the thresh-
old it fell on (that is, which class mean it was closest to)
was determined. The entire process was repeated so that
every specimen was omitted once and its class member-
ship was predicted; the number of misclassified speci-
mens was tallied. To determine whether the accuracy for
predicting membership of specimens in the two given
classes (as measured by the number of correct classifica-
tions) was better than the accuracy that could be attained
for predicting membership in random groupings of speci-
mens, we examined the distribution of the number of mis-
classifications for data sets in which the class labels were
permuted. Random data sets were created by permuting
class labels between the specimens, and cross-validated
class prediction was performed on the resulting data sets
as described above. The percentage of permutations that
resulted in no greater number of misclassifications than for
the original labeling of specimens was reported. If fewer
than 5% of the permutations resulted in as few or fewer
misclassifications, the accuracy of prediction into the
given classes was considered significant.
RT–PCR
Primers and probes (BioServe Biotechnologies, Laurel,
Maryland, USA) were designed with Primer Express soft-
ware (Applied Biosystems). Probes were 5′-labeled with
6-carboxyfluorescein (FAM) and 3′-labeled with 6-car-
boxytetramethylrhodamine (TAMRA). Sequences were as
follows. CD44: sense, 5′-TCACCAAATGCACCATTTCCT-
3′; antisense, 5′-GTGATCAACAGTGGCAATGGA-3′; probe,
5′-ACTTGCTGGCCTCTCCGTTGAGTCC-3′. COX17:
sense, 5′-CGAGGCTGGCATAGATTTGG-3′; antisense,
5′-AACCAGACCCGGCATCTTTC-3′; probe, 5′-TGTCTC-
CGCTCATAGCTGCTTTTGGC-3′. HMG1: sense, 5′-GCG-
GACAAGGCCCGTTA-3′; antisense, 5′-AGAGGAAGAA-
GGCCGAAGGA-3′; probe, 5′-AAAGAAGTTCAAGGA-
TCCCAATGCACCC-3′. cDNA was generated from ampli-
fied RNA samples (2 ng per assay) by using MultiScribe
reverse transcriptase and random hexamers for priming
(Applied Biosystems). Reaction conditions were 10 min at
25°C, 30 min at 48°C, and 5 min at 95°C. PCR reactions
were conducted in a volume of 25 µl by using AmpliTaq
Gold DNA polymerase (Applied Biosystems), with sense
and antisense primer concentrations of 900 nM each and
a probe concentration of 250 nM. Thermal cycler parame-
ters were 2 min at 50°C, 10 min at 95°C, and 40 cycles
each consisting of a 15 s denaturing step at 95°C and a
1 min annealing/extension step at 60°C. All assays were
performed in triplicate.
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